T1 Biomarker 593 598 PARPi
T2 Biomarker 1257 1272 ERCC1-deficient
T3 Level 1024 1030  TNBC 
T4 Biomarker 28 38 stimulator
T6 Protein 58 63 STING
T7 Cancer cells 701 708  NSCLC 
T8 Level 204 210  cells
T9 Level 1029 1035  cells
T10 Protein 42 51 IFN genes
T11 Level 304 323 isogenic cell lines
T12 Biomarker 1334 1339 PARPi
T14 Biomarker 4 27 cyclic GMP-AMP synthase
T15 Level 1221 1227  cells
T17 Biomarker 1085 1094 on-target
T18 Level 764 770  cells
T19 Biomarker 1105 1110 PARPi
T20 Protein 952 956 CCL5
T21 Level 1114 1119 PARP1
T22 Level 1014 1019 PARP1
T23 Cancer cells 712 758 BRCA1-defective triple-negative breast cancer 
T24 Condition 283 288 ERCC1
T25 Level 1178 1194 NSCLC cell lines
T26 Condition 1257 1262 ERCC1
T27 Biomarker 789 794 PARPi
T28 Protein 908 913 STING
T29 Biomarker 1121 1126 PARPi
T30 Cellular_component 805 836 cytoplasmic chromatin fragments
T31 Cancer cells 1177 1184  NSCLC 
T32 Level 198 210 cancer cells
T33 Level 418 424  cells
T34 Gene 91 94 DNA
T35 Condition 368 373 ERCC1
T36 Condition 264 279 BRCA1 mutations
T37 Level 537 548 lymphocytic
T38 Protein 1384 1395 molecularly
T39 Protein 445 480 type I IFN transcriptomic signature
T41 Level 1208 1227 patient tumor cells
T42 Condition 494 499 ERCC1
T43 Condition 686 691 ERCC1
T44 Gene 53 57 cGAS
T45 Intervention 861 872 micronuclei
T46 Protein 148 171  polymerase inhibitors 
T47 Gene 1144 1163 IFN-γ–induced PD-L1
T48 Cancer cells 368 411 ERCC1-defective non–small cell lung cancer 
T49 Condition 686 707 ERCC1-defective NSCLC
T50 Biomarker 172 177 PARPi
T51 Level 328 351 patient-derived samples
